Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Nov;39(11):2503–2510. doi: 10.1128/aac.39.11.2503

Comparison of the bactericidal activities of ofloxacin and ciprofloxacin alone and in combination with ceftazidime and piperacillin against clinical strains of Pseudomonas aeruginosa.

M E Klepser 1, K B Patel 1, D P Nicolau 1, R Quintiliani 1, C H Nightingale 1
PMCID: PMC162973  PMID: 8585734

Abstract

On the basis of MIC data, ciprofloxacin exhibits superior activity against Pseudomonas aeruginosa than the other currently available fluoroquinolones do. Despite the antipseudomonal advantage noted for ciprofloxacin monotherapy, it is unknown whether this advantage is maintained when the fluoroquinolones are used in combination with antipseudomonal beta-lactams such as ceftazidime and piperacillin. Twelve healthy volunteers were enrolled in this open-label, randomized, steady-state, six-way cross-over, comparative trial. All subjects received the following regimens: (i) 400 mg of ofloxacin given intravenously (i.v.) every 12 h (q12h), (ii) 400 mg of ciprofloxacin given i.v. q12h, (iii) 400 mg of ofloxacin given i.v. q12h plus 1 g of ceftazidime given i.v. every 8 h (q8h), (iv) 400 mg of ciprofloxacin given i.v. q12h plus 1 g of ceftazidime given i.v. q8h, (v) 400 mg of ofloxacin given i.v. q12h plus 4 g of piperacillin given i.v. q8h, and (vi) 400 mg of ciprofloxacin given i.v. q12h plus 4 g of piperacillin given i.v. q8h. Serum bactericidal titers with subsequent calculation of the area under the bactericidal curve were determined against three clinical isolates of P. aeruginosa. As monotherapy, ciprofloxacin demonstrated superior antipseudomonal activity than ofloxacin did; however, combination of these agents with ceftazidime yielded remarkably similar and statistically comparable activity profiles. In contrast, ciprofloxacin-piperacillin retained a bactericidal advantage over ofloxacin-piperacillin. Although ciprofloxacin exhibits superior antipseudomonal activity when used as monotherapy, combination of ofloxacin or ciprofloxacin with ceftazidime yielded equivalent activity profiles against susceptible strains of P. aeruginosa.

Full Text

The Full Text of this article is available as a PDF (685.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barriere S. L., Catlin D. H., Orlando P. L., Noe A., Frost R. W. Alteration in the pharmacokinetic disposition of ciprofloxacin by simultaneous administration of azlocillin. Antimicrob Agents Chemother. 1990 May;34(5):823–826. doi: 10.1128/aac.34.5.823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Blaser J., Stone B. B., Zinner S. H. Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro model. Antimicrob Agents Chemother. 1985 Mar;27(3):343–349. doi: 10.1128/aac.27.3.343. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bustamante C. I., Wharton R. C., Wade J. C. In vitro activity of ciprofloxacin in combination with ceftazidime, aztreonam, and azlocillin against multiresistant isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1990 Sep;34(9):1814–1815. doi: 10.1128/aac.34.9.1814. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chalkley L. J., Koornhof H. J. Antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus determined by the killing curve method: antibiotic comparisons and synergistic interactions. Antimicrob Agents Chemother. 1985 Aug;28(2):331–342. doi: 10.1128/aac.28.2.331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chin N. X., Jules K., Neu H. C. Synergy of ciprofloxacin and azlocillin in vitro and in a neutropenic mouse model of infection. Eur J Clin Microbiol. 1986 Feb;5(1):23–28. doi: 10.1007/BF02013456. [DOI] [PubMed] [Google Scholar]
  6. Davies G. S., Cohen J. In-vitro study of the activity of ciprofloxacin alone and in combination against strains of Pseudomonas aeruginosa with multiple antibiotic resistance. J Antimicrob Chemother. 1985 Dec;16(6):713–717. doi: 10.1093/jac/16.6.713. [DOI] [PubMed] [Google Scholar]
  7. De Schepper P. J., Tjandramaga T. B., Mullie A., Verbesselt R., van Hecken A., Verberckmoes R., Verbist L. Comparative pharmacokinetics of piperacillin in normals and in patients with renal failure. J Antimicrob Chemother. 1982 Feb;9 (Suppl B):49–57. doi: 10.1093/jac/9.suppl_b.49. [DOI] [PubMed] [Google Scholar]
  8. Dudley M. N., Blaser J., Gilbert D., Mayer K. H., Zinner S. H. Combination therapy with ciprofloxacin plus azlocillin against Pseudomonas aeruginosa: effect of simultaneous versus staggered administration in an in vitro model of infection. J Infect Dis. 1991 Sep;164(3):499–506. doi: 10.1093/infdis/164.3.499. [DOI] [PubMed] [Google Scholar]
  9. Espinoza A. M., Chin N. X., Novelli A., Neu H. C. Comparative in vitro activity of a new fluorinated 4-quinolone, T-3262 (A-60969). Antimicrob Agents Chemother. 1988 May;32(5):663–670. doi: 10.1128/aac.32.5.663. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Flaherty J. P., Waitley D., Edlin B., George D., Arnow P., O'Keefe P., Weinstein R. A. Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients. Am J Med. 1989 Nov 30;87(5A):278S–282S. doi: 10.1016/0002-9343(89)90080-6. [DOI] [PubMed] [Google Scholar]
  11. Lettieri J. T., Rogge M. C., Kaiser L., Echols R. M., Heller A. H. Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses. Antimicrob Agents Chemother. 1992 May;36(5):993–996. doi: 10.1128/aac.36.5.993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Maiche A. G., Teerenhovi L. Empiric treatment of serious infections in patients with cancer: randomised comparison of two combinations. Infection. 1991;19 (Suppl 6):S326–S329. doi: 10.1007/BF01715773. [DOI] [PubMed] [Google Scholar]
  13. Moody J. A., Gerding D. N., Peterson L. R. Evaluation of ciprofloxacin's synergism with other agents by multiple in vitro methods. Am J Med. 1987 Apr 27;82(4A):44–54. [PubMed] [Google Scholar]
  14. Paradis D., Vallée F., Allard S., Bisson C., Daviau N., Drapeau C., Auger F., LeBel M. Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin. Antimicrob Agents Chemother. 1992 Oct;36(10):2085–2092. doi: 10.1128/aac.36.10.2085. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Samuelsson J., Nilsson P. G., Wahlin A., Lerner R., Winqvist I., Palmblad J. A pilot study of piperacillin and ciprofloxacin as initial therapy for fever in severely neutropenic leukemia patients. Scand J Infect Dis. 1992;24(4):467–475. doi: 10.3109/00365549209052633. [DOI] [PubMed] [Google Scholar]
  16. Stratton C. W., Franke J. J., Weeks L. S., Manion F. A. Comparison of the bactericidal activity of ciprofloxacin alone and in combination with selected antipseudomonal beta-lactam agents against clinical isolates of Pseudomonas aeruginosa. Diagn Microbiol Infect Dis. 1988 Sep;11(1):41–52. doi: 10.1016/0732-8893(88)90072-7. [DOI] [PubMed] [Google Scholar]
  17. Wolfson J. S., Hooper D. C. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev. 1989 Oct;2(4):378–424. doi: 10.1128/cmr.2.4.378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Yuk J. H., Nightingale C. H., Quintiliani R., Sweeney K. R. Bioavailability and pharmacokinetics of ofloxacin in healthy volunteers. Antimicrob Agents Chemother. 1991 Feb;35(2):384–386. doi: 10.1128/aac.35.2.384. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Zhanel G. G., Hoban D. J., Harding G. K. The postantibiotic effect: a review of in vitro and in vivo data. DICP. 1991 Feb;25(2):153–163. doi: 10.1177/106002809102500210. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES